Fertility testing for employers: how lab work fits into a fertility benefit
Fertility benefits have moved from a rare perk to a standard part of many benefits packages. Most of the attention goes to the big-ticket items: IVF cycles, medications and egg freezing. The lab work before and during treatment gets less airtime, even though it sets the pace of care.
For HR leaders, benefits consultants and fertility-benefit platforms, testing is worth planning on purpose. This guide covers what a typical workup includes, where programs tend to stumble, and how to keep employee health data where it belongs.
Why lab testing deserves its own line in a fertility benefit
Testing is usually the first clinical step a member takes after enrolling. If it's slow, confusing or hard to reach, people stall before they ever see a specialist.
It also repeats. A fertility journey can include an initial diagnostic workup, infectious disease screening before treatment, and frequent hormone checks during a stimulation cycle. A benefit that covers IVF but treats bloodwork as an afterthought can leave members facing surprise bills or delays at the moments that matter most.
Start with an inclusive definition of who's eligible
Eligibility rules decide who can use testing in the first place. The American Society for Reproductive Medicine's 2023 definition of infertility includes people who need medical intervention, such as donor gametes or donor embryos, to achieve a pregnancy as an individual or with a partner. It also states that the definition shouldn't be used to deny or delay treatment based on relationship status or sexual orientation.
For employers, that matters in practice. Plans that require a year of "unprotected intercourse" before any testing is covered can shut out LGBTQ+ employees and single parents by choice. ASRM's definition still gives timing guidance for couples without a known cause: evaluation at 12 months when the female partner is under 35, and at 6 months when she's 35 or older.
What a typical initial workup includes
The exact tests are a clinical decision, but most initial evaluations follow a familiar pattern. Based on ASRM's committee opinion on evaluating infertile women and the AUA/ASRM male infertility guideline, common components include:
Ovarian reserve testing, usually anti-Müllerian hormone (AMH), or FSH and estradiol drawn early in the cycle
Ovulation and endocrine checks, such as progesterone, thyroid-stimulating hormone and prolactin when a clinician suspects ovulatory dysfunction
Semen analysis for a male partner, since the AUA/ASRM guideline recommends assessing both partners at the same time rather than one after the other
Infectious disease screening that clinics typically require before treatment, and that has its own rules when donor eggs or sperm are involved
That last point about concurrent testing is easy to miss in benefit design. If a plan only covers the employee, and not a spouse or partner on a different plan, the male-factor side of the workup can get delayed.
AMH is useful, but it isn't a fertility forecast
AMH is often the first fertility test employers hear about, and it's genuinely useful: ASRM's committee opinion on ovarian reserve testing describes AMH as a sensitive marker of ovarian reserve that can be drawn on any day of the cycle and helps predict how many eggs an IVF cycle may yield.
ASRM is equally clear about the limits. Ovarian reserve testing doesn't have proven benefits in women without infertility, and a low result in that group doesn't predict short-term chances of conceiving. Age remains the single most important predictor.
For a benefits team, the takeaway is about messaging. Positioning AMH testing as a way to "find out how fertile you are" oversells the test and can cause unnecessary worry. Framing it as one input into a conversation with a clinician is both more accurate and more useful.
Design questions to settle before launch
Whether you run the benefit in-house or through a fertility-benefit platform, these questions shape the member experience:
Who orders the tests? Lab testing should flow from a licensed clinician, whether that's the member's own provider, a fertility clinic or a telehealth practice built into the program.
Where does collection happen? Options include in-clinic draws, patient service centers and, for some validated tests, at-home collection. Many programs mix these based on where employees live.
How do results reach the care team? Results should go to the ordering clinician quickly and in a format their systems can use, not sit in a separate portal the clinic never checks.
How is repeat testing handled? Monitoring bloodwork during a treatment cycle is time-sensitive. Find out whether your coverage handles it as part of treatment or as separate lab claims.
What happens across state lines? A distributed workforce may need different collection options in different regions, and lab licensing varies by state.
Keep individual results away from the employer
Fertility data is some of the most sensitive health information an employee can share. The good news is that a well-designed program never needs to put individual results in front of HR.
According to HHS guidance on HIPAA and workplace wellness programs, HIPAA applies to group health plans rather than to employers acting as employers. When a program runs through a group health plan, an employer serving as plan sponsor can access protected health information only for plan administration, and only after certifying it won't use that information for employment decisions. When a program sits outside the health plan, HIPAA may not apply at all, though other federal and state laws might.
A few practical safeguards:
Route orders and results between the lab, the clinician and the member, not through HR
Ask vendors to confirm whether they act as a HIPAA business associate and how they separate plan data from employment data
Limit employer reporting to de-identified, aggregate information
Measure the program without measuring people
You can still track whether testing is working without looking at anyone's results. Useful aggregate measures include:
Time from enrollment to first lab draw
Share of members whose initial workup includes both partners, where applicable
Average time from sample collection to results reaching the clinician
Member satisfaction with the testing step
These numbers point to bottlenecks, such as poor collection access in one region, without exposing anyone's health information.
A note for California employers
California's SB 729 changes the baseline for many employers in the state. As summarized by the bill's author, Senator Caroline Menjivar, it requires state-regulated large group health plans to cover the diagnosis and treatment of infertility, including IVF, for contracts issued or renewed on or after January 1, 2026. It also updates the definition of infertility to include LGBTQ+ and unpartnered people, following ASRM's approach.
Self-funded plans generally fall outside state insurance mandates, so employers should confirm with their broker or carrier how the law applies to them.
Bringing it together
Lab testing is a small part of a fertility benefit's cost, but it sets the pace for everything that follows. Inclusive eligibility, a complete workup for both partners, realistic messaging around tests like AMH, and strong privacy boundaries go a long way toward a benefit employees trust.
Labs that work with fertility programs, including IHDLab, a CLIA-certified lab licensed in California, New York and Maryland, can help benefits teams map these steps to real collection and reporting workflows. If you're planning or revisiting a program, our overview of fertility and IVF lab testing is a good place to start.
This article is for general educational purposes and isn't medical or legal advice. Talk with qualified clinicians and benefits counsel about your specific program.
